Blood Centers Seek Action On Assay Standards, Reentry Algorithms
This article was originally published in The Gray Sheet
There is little incentive in the current regulatory environment for manufacturers to improve the specificity and sensitivity of blood borne pathogen screening assays, American Red Cross Executive Scientific Officer Susan Stramer, PhD, maintained at a Dec. 5 FDA workshop on nucleic acid testing (NAT) in Bethesda, Maryland
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.